2225 — Jinhai Medical Technology Balance Sheet
0.000.00%
- HK$6.40bn
- HK$6.45bn
- SG$50.24m
Annual balance sheet for Jinhai Medical Technology, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 25.7 | 25 | 23.9 | 26.8 | 14.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.31 | 2.67 | 4.03 | 8.42 | 9.22 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32.4 | 30.7 | 33.3 | 42.7 | 30.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.29 | 1.83 | 5.73 | 6.43 | 6.3 |
| Net Goodwill | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 39.4 | 33.8 | 40.3 | 62.2 | 58.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13.2 | 9.47 | 14 | 21.3 | 23.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Liabilities | 13.9 | 9.49 | 15.9 | 24.7 | 27.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 25.5 | 24.3 | 24.4 | 37.5 | 31.8 |
| Total Liabilities & Shareholders' Equity | 39.4 | 33.8 | 40.3 | 62.2 | 58.9 |
| Total Common Shares Outstanding |